|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Randomized trial in malignant biliary obstruction:Plastic vs partially covered metal stents显示文摘AIM:To compare efficacy and complications of par-tially covered self-expandable metal stent(pcSEMS)to plastic stent(PS)in patients treated for malignant,infrahilar biliary obstruction.METHODS:Multicenter prospective randomized clinical trial with treatment allocation to a pcWallstent(SEMS)or a 10 French PS.Palliative patients aged≥18,for infrahilar malignant biliary obstruction and a Karnofsky performance scale index>60%from 6 participating North American university centers.Primary endpoint was time to stent failure,with secondary outcomes of death,adverse events,Karnofsky performance score and short-form-36 scale administered on a three-monthly basis for up to 2 years.Survival analyses were performed for stent failure and death,with Cox proportional hazards regression models to determine significant predictive characteristics.RESULTS:Eighty-five patients were accrued over 37mo,42 were randomized to the SEMS group and 83patients were available for analyses.Time to stent failure was 385.3±52.5 d in the SEMS and 153.3±19.8 d in the PS group,P=0.006.Time to death did not differ between groups(192.3±23.4 d for SEMS vs211.5±28.0 d for PS,P=0.70).The only significant predictor was treatment allocation,relating to the time to stent failure(P=0.01).Amongst other measured outcomes,only cholangitis differed,being more common in the PS group(4.9%vs 24.5%,P=0.029).The small number of patients in follow-up limits longitudinal assessments of performance and quality of life.From an initially planned 120 patients,only 85 patients were recruited.CONCLUSION:Partially covered SEMS result in a longer duration till stent failure without increased complication rates,yet without accompanying measurable benefits in survival,performance,or quality of life. | Peter L Moses Khalid M AlNaamani Alan N Barkun Stuart R Gordon Roger D Mitty M Stanley Branch Thomas E Kowalski Myriam Martel Viviane Adam | 2013 | World Journal of Gastroenterology2013，19，46： | 6 |
| 2 | Review of primary sclerosing cholangitis with increased IgG4 levels显示文摘Primary sclerosing cholangitis(PSC) is a chronic progressive liver disease. Subtypes of PSC have been described, most recently PSC with elevated serum and/or tissue IgG4 subclass. We aim to summarise the clinical phenotype,disease associations, differential diagnosis, response to therapy and pathogenic mechanisms underlying PSC-high IgG4 subtype. We reviewed Pub Med,MEDLINE and Embase with the search terms 'primary sclerosing cholangitis','IgG4', and 'IgG4-related sclerosing cholangitis(IgG4-SC)'. Elevated serum IgG4 are found in up-to one-quarter, and abundant IgG4-plasma cell infiltrates in the liver and bile ducts are found in up-to one-fifth of PSC patients. This group have a distinct clinical phenotype, with some studies reporting a more aggressive course of liver and associated inflammatory bowel disease, compared to PSCnormal IgG4 and the disease mimic IgG4-SC. Distinguishing PSC-high IgG4 from IgG4-SC remains challenging, requiring careful assessment of clinical features,organ involvement and tissue morphology. Calculation of serum IgG4:IgG1 ratios and use of a novel IgG4:IgG RNA ratio have been reported to have excellent specificity to distinguish IgG4-SC and PSC-high IgG4 but require validation in larger cohorts. A role for corticosteroid therapy in PSC-high IgG4 remains unanswered, with concerns of increased toxicity and lack of outcome data. The immunological drivers underlying prominent IgG4 antibodies in PSC are incompletely defined. An association with PSC-high IgG4 and HLA class-II haplotypes(B*07, DRB1*15), T-helper2 and T-regulatory cytokines(IL4, IL10,IL13) and chemokines(CCL1, CCR8) have been described. PSC-high IgG4 have a distinct clinical phenotype and need careful discrimination from IgG4-SC,although response to immunosuppressive treatments and long-term outcome remains unresolved. The presence of IgG4 likely represents chronic activation to persistent antigenic exposure in genetically predisposed individuals. | Charis D Manganis Roger W Chapman Emma L Culver | 2020 | World Journal of Gastroenterology2020，26，23： | 5 |
| 3 | DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice显示文摘 | Meira Lisiane B Bugni James M Green Stephanie L Lee Chung-Wei Pang Bo Borenshtein Diana Rickman Barry H Rogers Arlin B Moroski-Erkul Catherine A McFaline Jose L Schauer David B Dedon Peter C Fox James G Samson Leona D | 2008 | Journal of Clinical Investigation2008，，7： | 2 |
| 4 | Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis显示文摘Patients with severe alcoholic hepatitis (AH) need to be treated with specific treatment for better outcome.Currently available specific treatment modalities are use of corticosteroids or pentoxifylline.However,the response rate to these drugs is only about 50%-60%.Hence,there is an urgent need for better and more effective treatment options.Tumor necrosis factor plays an important role in the pathogenesis of AH.However,agents blocking the action of tumor necrosis factor have not been found to be effective.Rather the randomized studies evaluating these agents showed an adverse effect and more infections in treated patients.Critical role of tumor necrosis factor in hepatic regen-eration explaining this contrast is discussed.Oxidative stress and inflammation derived from gut bacteria ate two main components in the pathogenesis of AH laying foundation for the role of antioxidants,probiotics,and antibiotics in the management of AH.This article reviews the current data and status of these newer agents for the treatment of AH.Of the various options available,Vitamin E and N-acetylcysteine (NAC) have shown great promise for clinical use as adjunct to corticosteroids.With these encouraging data,future well designed studies are suggested to assess Vitamin E and NAC before their routine use in clinical practice in the management of AH. | Gabriel L Reep Roger D Soloway | 2011 | World Journal of Hepatology2011，3，8： | 2 |
| 5 | The Supply Chain Management Process显示文摘 | Croxton K L Garcfa - Dastugue S J Lambert D M Rogers | 2001 | The International Jour- nal of Logistics Management2001，12，2： | 1 |
| 6 | Deciphering the biology of My cobacterium tuberculosis from the complete genome sequence 显示文摘 | Cole S T Brosch R Parkhill J Gamier T Churcher C Harris D Gordon S V Eiglmeier K Gas S Barry C E Tekaia F Badcock K Basham D Brown D Chillingworth T Cormor R Davies R Devlin K FeltweU T Gentles S Hamlin N Holroyd S Hornsby T Jagels K Kroghs A McLean J Moule S Murphy L Oliver K Osborne J Quail M A Rafandream M A Rogers J Rutter S Seeger K Skelton J Squaraes R Squares S Sulston J E Taylo K Whitehead S Barrell B G | 1998 | Nature1998，393，： | 1 |
| 7 | Molecular and cellular regula- tion of glucose transporter (Glut) proteins in cancer 显示文摘 | Maeheda M L Rogers S Best J D | 2005 | J Cell Physiol2005，202，3： | 1 |
| 8 | Prostanoids in platelet vascularinteractions显示文摘 | Martin JJ Lan L Smith Roger D | 1983 | Am J Cardiol1983，5，2： | 1 |
| 9 | Age-associated change in regional aortic pulse wave velocity显示文摘 | ROGERS W HU Y L COAST D | 2001 | Am Coll Cardiol2001，38，4： | 1 |
| 10 | Heart disease and stroke statistics-2013 update: a report from the American Heart Association 显示文摘 | GO A S MOZAFFARIAN D ROGER V L | 2013 | Circulation2013，127，1： | 1 |
| 11 | Heart disease and stroke statistics---2013 update:a report from the American Heart Association显示文摘 | Go A S Mozaffarian D Roger V L | | 0，，01： | 1 |
| 12 | A Pedagogical Treatment of Bilateral Monopoly 显示文摘 | Roger D Blair David L Kaserman Richard E Romano | 1989 | Southern Economic Journal1989，55，4： | 1 |
| 13 | Significance of reservoir bitumens to thermal maturation studies,Western Canada Basin显示文摘 | Rogers M A McAlary J D Bailey N J L | 1974 | AAPG Bulletin1974，58，9： | 1 |
| 14 | Analyses of genes that encode the 15 kDa sein protein of maize:identification of potential gene regulatory elements显示文摘 | Roger F D Jerry L S | | 0，，： | 1 |
| 15 | Molecular and cellular reg- ulation of glucose transporter(GLUT)proteins in cancer显示文摘 | Macheda M L Rogers S Best J D | 2005 | J Cell Physiol2005，202，3： | 1 |
| 16 | Multidisciplinary Techniques and Novel Aircraft Control Systems显示文摘 | Padula S L Rogers J L Raney D L | 2000 | AIAA 2000-48482000，，： | 1 |
| 17 | Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence 显示文摘 | Cole ST Brosch R Parkhill J Garnier T Churcher C Harris D Gordon SV Eiglmeier K Gas S Barry CE Tekaia F Badcock K Basham D Brown D Chillingworth T Connor R Davies R Devlin K Feltwell T Gentles S Hamlin N Holroyd S Hornsby T Jagels K Krogh A Mclean J Moule S Murphy L Oliver K Osborne J Quail MA Rajandream MA Rogers J Rutter S Seeger K Skelton J Squares R Squares S Sulston JE Taylor K Whitehead S Barrell BG | 1998 | Nature1998，393，6685： | 1 |
| 18 | American Heart Association Statistics Committee and Stroke Statis- tics Subcommittee: Heart disease stroke statistics-2011 update A report from the American Heart Association显示文摘 | Roger V L Go A S Lloyd-Jones D M | 2011 | Circulation2011，123，： | 1 |
| 19 | Rapamycin inhibits lymphatic en-dothelial cell tube formation by downregulating vascular endothelial growth factor receptor3protein expression显示文摘 | LLuo Y Liu L Rogers D | 2012 | Neoplasia2012，14，3： | 1 |
| 20 | The effect of neoprene shorts on leg proprioception in Australian football players显示文摘 | MATTHEW L CAMERON ROGER D ADAMS CHRIS G MAHER B | 2008 | Journal of Science and Medicine in Sport2008，11，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员